Valuation: Emergent BioSolutions Inc.

Market Cap 394M 344M 317M 293M 552M 37.91B 564M 3.79B 1.49B 18.57B 1.48B 1.45B 63.92B P/E 2026 *
-25x
P/E 2027 * 8.38x
Enterprise Value 394M 344M 317M 293M 552M 37.91B 564M 3.79B 1.49B 18.57B 1.48B 1.45B 63.92B EV / Sales 2026 *
0.54x
EV / Sales 2027 * 0.44x
Free-Float
81.07%
Yield 2026 *
-
Yield 2027 * -
06-29 Emergent BioSolutions Secures Contract Modification Valued At Approximately USD 52.7 Million From The United States Department Of Health And Human Services To Supply ACAM2000 CI
06-29 Emergent Gets $52.7 Million Contract Modification From US Government MT
06-08 Emergent BioSolutions Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 02:00 PM
05-28 Emergent BioSolutions Wins $64.5 Million US Government Contract Modification for BAT MT
05-28 Emergent BioSolutions receives $64.5 million contract modification for BAT® to support U.S. biodefense strategy RE
05-28 Emergent BioSolutions Inc. Receives USD 64.5 Million Contract Modification from the Administration for Strategic Preparedness and Response for Supply of BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) ?] CI
05-18 Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for Smallpox, Mpox Vaccine MT
05-18 Emergent BioSolutions Receives Saudi Food And Drug Authority Approval For ACAM2000 CI
05-01 Emergent BioSolutions Inc., Q1 2026 Earnings Call, Apr 30, 2026
04-30 Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on May 7, 2025. CI
04-30 Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on February 26, 2026. CI
04-30 Emergent BioSolutions Inc. Provides Earnings Guidance for the Second Quarter and Updates Earnings Guidance for Full Year 2026 CI
04-30 Emergent BioSolutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
1 day-0.78%
1 week-5.22%
Current month-8.95%
1 month-4.62%
3 months-13.39%
6 months-30.57%
Current year-38.27%
1 week 7.39
Extreme 7.39
8.15
1 month 7.39
Extreme 7.39
8.63
Current year 7.39
Extreme 7.39
14.06
1 year 5.62
Extreme 5.615
14.06
3 years 1.42
Extreme 1.42
15.1
5 years 1.42
Extreme 1.42
68.03
10 years 1.42
Extreme 1.42
137.61
Manager TitleAgeSince
Chief Executive Officer 70 2024-02-20
Director of Finance/CFO 62 2018-03-25
Chief Tech/Sci/R&D Officer 53 2024-11-17
Director TitleAgeSince
Chairman 82 2022-03-31
Director/Board Member 70 2004-12-31
Director/Board Member 77 2016-09-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Executive/Senior Manager

-3,000 0.0058%
6/8/26 Tax

Executive/Senior Manager

-694 0.0013%
6/8/26 Tax

Chief Financial Officer

-3,964 0.0077%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-5.22%+10.10%+8.23% 394M
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.14%-0.04%+26.69%+49.34% 357.55B
Weighted average by Cap. +0.37%+0.02%+37.51%+79.62%

Financials

2026 *2027 *
Net sales 733M 641M 591M 545M 1.03B 70.59B 1.05B 7.07B 2.78B 34.57B 2.75B 2.69B 119B 892M 780M 719M 663M 1.25B 85.9B 1.28B 8.6B 3.38B 42.07B 3.35B 3.28B 145B
Net income -15.98M -13.97M -12.89M -11.88M -22.39M -1.54B -22.89M -154M -60.59M -754M -60.02M -58.71M -2.6B 47.92M 41.88M 38.64M 35.62M 67.14M 4.61B 68.63M 462M 182M 2.26B 180M 176M 7.78B
Net Debt - -
Logo Emergent BioSolutions Inc.
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Employees
900
Date Price Change Volume
26-07-17 US$7.630 -0.78% 604,326
26-07-16 US$7.690 -2.53% 846,912
26-07-15 US$7.890 +5.20% 861,704
26-07-14 US$7.500 -6.37% 1,204,676
26-07-13 US$8.010 -0.50% 675,731
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.630USD
Average target price
12.00USD
Spread / Average Target
+57.27%

Quarterly revenue - Rate of surprise